When evaluating whether therapeutic drug monitoring is needed for a new orally administered drug, which factors should be considered?

When evaluating whether therapeutic drug monitoring is needed for a new orally administered drug, which factors should be considered?

• A. Proximity of toxic range to therapeutic range
• B. Consequences of subtherapeutic concentration in circulation
• C. Severity of toxic adverse effects
• D. All of the above should be taken into consideration

Answer: (D)

Therapeutic drug monitoring is most useful when there is a clear exposure–response relationship and a narrow safety margin. If the toxic range sits close to the therapeutic range, even small changes in drug level due to absorption, metabolism, or interactions can tip a patient into toxicity or fall below efficacy, so monitoring helps keep levels in a safe, effective zone. The consequences of subtherapeutic concentrations matter because they can lead to treatment failure, relapse, or resistance, making monitoring valuable to ensure adequate exposure. The severity of potential toxic adverse effects also drives the need for monitoring; if toxicity could be serious or life-threatening, detecting and correcting high levels becomes crucial. For a new orally administered drug, patient-to-patient variability in pharmacokinetics and limited initial data heighten these concerns, so all of these factors should be considered when deciding whether therapeutic drug monitoring is warranted.

Therapeutic drug monitoring is most useful when there is a clear exposure–response relationship and a narrow safety margin. If the toxic range sits close to the therapeutic range, even small changes in drug level due to absorption, metabolism, or interactions can tip a patient into toxicity or fall below efficacy, so monitoring helps keep levels in a safe, effective zone. The consequences of subtherapeutic concentrations matter because they can lead to treatment failure, relapse, or resistance, making monitoring valuable to ensure adequate exposure. The severity of potential toxic adverse effects also drives the need for monitoring; if toxicity could be serious or life-threatening, detecting and correcting high levels becomes crucial. For a new orally administered drug, patient-to-patient variability in pharmacokinetics and limited initial data heighten these concerns, so all of these factors should be considered when deciding whether therapeutic drug monitoring is warranted.